Skip to NavigationSkip to content

Abcam acquires rights to over 700 Roche products in new licensing deal

Published on 22/01/18 at 10:59am

Roche has entered a licensing agreement Abcam which gives the British biotech exclusive access to the marketing rights for 760 of the Swiss pharma giant’s products, all of which are for research use only (RUO).

The full range of products represents the complete portfolio of Spring Bioscience Corporation, a California-based biotech that Roche acquired in 2007, and includes 243 antibodies for use in rabbits, in addition to more than 500 other antibodies.

As part of the deal, Abcam will have the rights to any future antibodies developed by Spring which Roche decides to commercialise for an initial period of 10 years. Roche retains the right to use antibodies for internal research and as companion diagnostic tools.

Abcam will begin commercialising and selling the acquired antibodies from 21 February.

The deal marks the latest in a series of moves by Abcam to expand its portfolio, which now includes more than 120,000 products. Since 2011, the biotech has made a number of acquisitions to this end, including AxioMx, Ascent Scientific, Epitomics, Firefly Bioworks and MitoSciences.

Matt Fellows

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches